
Ecabet Sodium
CAS No. 86408-72-2
Ecabet Sodium( —— )
Catalog No. M16263 CAS No. 86408-72-2
Ecabet sodium: a potential new agent in the management of distal colitis.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
10MG | 39 | Get Quote |
![]() ![]() |
50MG | 87 | Get Quote |
![]() ![]() |
100MG | 129 | Get Quote |
![]() ![]() |
200MG | 188 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameEcabet Sodium
-
NoteResearch use only, not for human use.
-
Brief DescriptionEcabet sodium: a potential new agent in the management of distal colitis.
-
DescriptionEcabet sodium: a potential new agent in the management of distal colitis.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number86408-72-2
-
Formula Weight402.48
-
Molecular FormulaC20H27NaO5S
-
Purity>98% (HPLC)
-
SolubilityDMSO: 10 mM
-
SMILESCC(C)C1=C(C=C2C(=C1)CC[C@@H]3[C@@]2(CCC[C@@]3(C)C(=O)O)C)S(=O)(=O)[O-].[Na+]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference



-
7-Hydroxyaristolochi...
7-Hydroxyaristolochic acid A is a natural product from Aristolochia debilis Sieb.
-
24-Norursodeoxycholi...
24-norursodeoxycholic acid is a side chain-shortened C23 homolog of UDCA.It has shown potent anti-inflammatory, anti-cholestatic, and anti-fibrotic properties.It is a Ursodeoxycholic Acid derivative. It is superior to Ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice24-norUrsodeoxycholic acid markedly improved liver tests and liver histology and significantly reduced hydroxyproline content and the number of infiltrating neutrophils and proliferating hepatocytes and cholangiocytes.?
-
Tranilast
A compound that exhibits anti-inflammatory and immunomodulatory effects by inhibiting lipid mediator and cytokine release from inflammatory cells and interfering with PDGF- and TGF-β1-induced proliferation and migration of vascular medial smooth muscle cells.